Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives

IJC Heart and Vessels

Volumn 3, Issue , 2014, Pages 6-14

  Vizzardi, Enrico ^a   Regazzoni, Valentina ^a   Caretta, Giorgio ^a   Gavazzoni, Mara ^a   Sciatti, Edoardo ^a   Bonadei, Ivano ^a   Trichaki, Eleftheria ^a   Raddino, Riccardo ^a   Metra, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Aldosterone; Guidelines; Heart failure; Mineralocorticoid receptor antagonists; Prognosis

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN II; APOPTOSIS SIGNAL REGULATING KINASE 1; CANRENONE; COLLAGEN; CORTICOTROPIN; CYTOCHROME P450 3A4; ELASTIN; EPITHELIAL GROWTH FACTOR RECEPTOR; EPLERENONE; EXTRACELLULARSIGNAL REGULATED KINASE 1; EXTRACELLULARSIGNAL REGULATED KINASE 2; FAD 286; FK 506 BINDING PROTEIN; HYDROCORTISONE; INTERSTITIAL COLLAGENASE; LCI 699; MATRIX METALLOPROTEINASE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; PATIROMER; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN KINASE; RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SM 368229; SPIRONOLACTONE; SPP 2745; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; CLARITHROMYCIN; FAD286; ITRACONAZOLE; KETOCONAZOLE; LCI699; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SPP2745;

APOPTOSIS; ARTERIAL STIFFNESS; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CATECHOLAMINE RELEASE; ENDOTHELIAL DYSFUNCTION; FIBROSIS; FLUID RETENTION; GYNECOMASTIA; HEART DISEASE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MASTALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM RETENTION; ACUTE HEART INFARCTION; ANTIARRHYTHMIC ACTIVITY; BREAST TENDERNESS; DRUG HALF LIFE; DRUG RESPONSE; ERECTILE DYSFUNCTION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM REMODELING; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CONGESTION; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; OXIDATIVE STRESS; PREGULATION;

EID: 84901284184     PISSN: 22147632     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijchv.2014.03.005     Document Type: Review

References (102)

1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
2. Brown N.J. Eplerenone: cardiovascular protection. Circulation 2003, 107:2512-2518.
3. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004, 6:539-545.
4. Mohammed S.F., Ohtani T., Korinek J., Lam C.S., Larsen K., Simari R.D., et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation 2010, 122:370-378.
5. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994, 26:809-820.
6. Fraccarollo D., Galuppo P., Bauersachs J. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. Curr Med Chem Cardiovasc Hematol Agents 2004, 2:287-294.
7. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz 2000, 25:299-306.
8. Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000, 32:865-879.
9. Nakamura T., Kataoka K., Fukuda M., Nako H., Tokutomi Y., Dong Y.F., et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009, 54:544-551.
10. Perico N., Benigni A., Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov 2008, 7:936-953.
11. Assomull R.G., Prasad S.K., Lyne J., Smith G., Burman E.D., Khan M., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006, 48:1977-1985.
12. Iles L., Pfluger H., Lefkovits L., Butler M.J., Kistler P.M., Kaye D.M., et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 2011, 57:821-828.
13. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215-262.
14. Gómez A.M., Rueda A., Sainte-Marie Y., Pereira L., Zissimopoulos S., Zhu X., et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009, 119:2179-2187.
15. Velagaleti R.S., Gona P., Sundström J., Larson M.G., Siwik D., Colucci W.S., et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010, 30:2283-2288.
16. Tang W.H., Parameswaran A.C., Maroo A.P., Francis G.S. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005, 80:1623-1630.
17. Cittadini A., Monti M.G., Isgaard J., Casaburi C., Strömer H., Di Gianni A., et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003, 58:555-564.
18. Schafer A., Fraccarollo D., Hildemann S.K., Tas P., Ertl G., Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003, 58:655-662.
19. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
20. Boccanelli A., Mureddu G.F., Cacciatore G., Clemenza F., Di Lenarda A., Gavazzi A., et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009, 11:68-76.
21. Modena M.G., Aveta P., Menozzi A., Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001, 141:41-46.
22. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
23. Pitt B., Anker S.D., Bushinsky D.A., Kitzman D.W., Zannad F., Huang I.Z., PEARL-HF Investigators Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011, 32:820-828.
24. + excretion activity. J Pharmacol Sci 2011, 115:346-353.
25. Steckelings U.M., Paulis L., Unger T., Bader M. Emerging drugs which target the renin-angiotensin-aldosterone system. Expert Opin Emerg Drugs 2011, 16:619-630.
26. Paulis L., Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010, 7:431-441.
27. Fiebeler A., Nussberger J., Shagdarsuren E., Rong S., Hilfenhaus G., Al-Saadi N., et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
28. Lea W.B., Kwak E.S., Luther J.M., Fowler S.M., Wang Z., Ma J., et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009, 75:936-944.
29. Mulder P., Mellin V., Favre J., Vercauteren M., Remy-Jouet I., Monteil C., et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008, 29:2171-2179.
30. Amar L., Azizi M., Menard J., Peyrard S., Watson C., Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010, 56:831-838.
31. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005, 10:15-22.
32. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
33. Vardeny O., Cavallari L.H., Claggett B., Desai A.S., Anand I., Rossignol P., et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013, 6:970-976.
34. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
35. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559-2565.
36. Palmer B.R., Pilbrow A.P., Frampton C.M., Yandle T.G., Skelton L., Nicholls M.G., et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008, 29:2489-2496.
37. Delyani J.A., Robinson E.L., Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001, 281:H647-H654.
38. Fletcher J., Buch A.N., Routledge H.C., Chowdhary S., Coote J.H., Townend J.N. Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol 2004, 43:1270-1275.
39. Rogers J.K., McMurray J.J., Pocock S.J., Zannad F., Krum H., van Veldhuisen D.J., et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation 2012, 126:2317-2323.
40. Krum H., Shi H., Pitt B., McMurray J., Swedberg K., van Veldhuisen D.J., et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013, 6:711-718.
41. Collier T.J., Pocock S.J., McMurray J.J., Zannad F., Krum H., van Veldhuisen D.J., et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013, 34:2823-2829.
42. Writing Committee Members, Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 128:e240-e319.
43. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
44. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., Atar D., Badano L.P., Blömstrom-Lundqvist C., Borger M.A., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33:2569-2619.
45. Vizzardi E., D'Aloia A., Giubbini R., Bordonali T., Bugatti S., Pezzali N., et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 2010, 106:1292-1296.
46. Udelson J.E., Feldman A.M., Greenberg B., Pitt B., Mukherjee R., Solomon H.A., et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010, 3:347-353.
47. Chan A.K., Sanderson J.E., Wang T., Lam W., Yip G., Wang M., et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007, 50:591-596.
48. Vizzardi E., Nodari S., Caretta G., et al. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci 2014, 347(4):271-276.
49. Meta-analysis Global Group in Chronic Heart F The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012, 33:1750-1757.
50. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
51. Desai A.S., Mitchell G.F., Fang J.C., Creager M.A. Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail 2009, 15:658-664.
52. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558-565.
53. Li X., Qi Y., Li Y., et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013, 6:156-165.
54. Grandi A.M., Imperiale D., Santillo R., et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647-652.
55. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
56. Shah S.J., Heitner J.F., Sweitzer N.K., et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013, 6:184-192.
57. Aldo-antagonist falls short but impresses in preserved-EF heart failure: TOPCAT 18 Nov 2013, Medscape.
58. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001, 37:662-667.
59. Brilla C.G., Weber K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992, 26:671-677.
60. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
61. Velagaleti R.S., Gona P., Levy D., Velagaleti R.S., Gona P., Levy D., et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008, 118:2252-2258. [5p following 8].
62. Leopold J.A. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011, 124:e466-e468.
63. Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001, 38:1222-1226.
64. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119:2471-2479.
65. Mak G.J., Ledwidge M.T., Watson C.J., et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009, 54:1674-1682.
66. Edwards N.C., Ferro C.J., Kirkwood H., et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010, 106:1505-1511.
67. Izawa H., Murohara T., Nagata K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940-2945.
68. Kosmala W., Przewlocka-Kosmala M., Szczepanik-Osadnik H., Mysiak A., Marwick T.H. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 2013, 99:320-326.
69. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
70. Laurent S., Katsahian S., Fassot C., et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003, 34:1203-1206.
71. Ooi H., Chung W., Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail 2008, 14:31-36.
72. Patrianakos A.P., Parthenakis F.I., Karakitsos D., Nyktari E., Vardas P.E. Proximal aortic stiffness is related to left ventricular function and exercise capacity in patients with dilated cardiomyopathy. Eur J Echocardiogr 2009, 10:425-432.
73. Bonapace S., Rossi A., Cicoira M., et al. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy. Circulation 2003, 107:1603-1608.
74. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005, 25:932-943.
75. Lacolley P., Labat C., Pujol A., Delcayre C., Benetos A., Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002, 106:2848-2853.
76. Nehme J.A., Lacolley P., Labat C., et al. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol 2005, 39:511-519.
77. Park S., Kim J.B., Shim C.Y., et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007, 25:1279-1283.
78. Baldo M.P., Forechi L., Morra E.A., et al. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep 2011, 63:975-982.
79. Kithas P.A., Supiano M.A. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc 2010, 58:1327-1332.
80. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
81. Ouvrard-Pascaud A., Sainte-Marie Y., Benitah J.P., et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111:3025-3033.
82. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46:425-431.
83. Bapoje S.R., Bahia A., Hokanson J.E., et al. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013, 6:166-173.
84. Perrier E., Kerfant B.G., Lalevee N., et al. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004, 110:776-783.
85. Hanna S., Mac I.I. The influence of aldosterone on magnesium metabolism. Lancet 1960, 2:348-350.
86. Gao X., Peng L., Adhikari C.M., Lin J., Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007, 13:170-177.
87. Antaloczy Z., Sebeszta M., Preda I. The effect of potassium canrenoate (aldactone) on the norepinephrine metabolism and potassium ionic currents of the heart. Adv Myocardiol 1982, 3:215-222.
88. Kasama S., Toyama T., Kumakura H., et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003, 41:574-581.
89. Milliez P., Deangelis N., Rucker-Martin C., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005, 26:2193-2199.
90. Shroff S.C., Ryu K., Martovitz N.L., Hoit B.D., Stambler B.S. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006, 17:534-541.
91. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005, 45:1832-1839.
92. Schneider M.P., Hua T.A., Bohm M., Wachtell K., Kjeldsen S.E., Schmieder R.E. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010, 55:2299-2307.
93. Swedberg K., Zannad F., McMurray J.J., et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012, 59:1598-1603.
94. Pitt B., Pitt G.S. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007, 115:2976-2982. [discussion 82].
95. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259-1265.
96. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001, 37:1228-1233.
97. Cicoira M., Zanolla L., Rossi A., et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002, 40:304-310.
98. Akbulut M., Ozbay Y., Ilkay E., Karaca I., Arslan N. Effects of spironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J 2003, 44:681-692.
99. Ozkara A., Turgut F., Selcoki Y., et al. Probrain natriuretic peptide for assessment of efficacy in heart failure treatment. Adv Ther 2007, 24:1233-1239.
100. Kasama S., Toyama T., Sumino H., et al. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007, 48:1993-2000.
101. Taheri S., Mortazavi M., Shahidi S., et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009, 20:392-397.
102. Kimura M., Ogawa H., Wakeyama T., et al. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. J Cardiol 2011, 57:208-214.